The number of patients receiving a BMT is currently being used as a factor in the accreditation process in determining whether a center can provide a high-quality BMT. Such criteria particularly impact pediatric BMT centers as most of them perform a relatively small number of BMTs. To determine whether patient volume is a valid marker of pediatric BMT center's capabilities, the Pediatric Blood and Marrow Transplant Consortium (PBMTC) evaluated data from its registry to define the relationship between a pediatric transplant center's patient volume and day þ 100 mortality. The analyses evaluated 2575 transplants from 60 centers reporting to the PBMTC between the years 2002 and 2004. The volume-outcome relationship was evaluated while adjusting for 46 independent data categories divided between nine variables that were known-or suspected-mortality risk factors. We found no association between transplant center volume and day þ 100 mortality in several analyses. A calculated intraclass correlation coefficient also indicated that differences in individual transplant center volume contributed to only 1% of the variance in day þ 100 mortality within the PBMTC. The results of this study suggest that factors other than transplant center volume contribute to variation in day þ 100 mortality among pediatric patients.
INTRODUCTION
The 'volume-outcome' association refers to the relationship between the quantity of care that a hospital or physician provides and the quality of care that a patient receives. The volumeoutcome relationship has been studied for a variety of disease processes and surgical conditions. 1 Although studies have found that hospitals and physicians treating more patients, including cancer patients, may have better outcomes, [2] [3] [4] other data support a clinically relevant relationship less consistently. [5] [6] [7] [8] [9] This is particularly true among studies that have investigated volumeoutcome relationships among hospitalized pediatric patients, 10, 11 including pediatric surgical cancer patients. 12 In the context of pediatric solid organ transplantation, increased volume has been associated with better outcomes in the context of cardiac transplantation and found to be a surrogate marker for the use of anti-T cell induction therapy for renal transplantation, but was not associated with liver transplant outcomes done in the context of a Children's Hospital. [13] [14] [15] Volume remains a core criterion for pediatric BMT center accreditation by national and international organizations, including the Foundation for Accreditation of Cellular Therapy (FACT) and the Joint Accreditation Committee of the International Society for Cell Therapy. 16 Payors for BMT also retain volume as a core criterion for 'excellence' as do state agencies (for example, California Children's Services). Center minimum volume criteria is thus a significant issue not just for individual, smaller transplant centers, but also for clinical data accrual to national studies and, potentially, for access to care by patients who would require significant travel if these procedures were available at only regional centers.
Pediatric BMT procedures represent a unique clinical situation wherein collaboration between large numbers of centers is necessary to study relatively rare diseases. 17 Limited patient numbers also compromise the evaluation of clinical situations, such as BMT procedures, that are impacted by multiple confounding variables. To date, data regarding pediatric BMTs are often derived from a single or limited institution experience, span a large time period and contain relatively homogeneous patient populations, or a combination, thereof. [18] [19] [20] It is unclear whether the observations reported from these studies are representative of the broader pediatric BMT experience. Thus, a dense data set from a broadbased patient population is necessary to best investigate the volume-outcome relationship for pediatric BMT procedures.
The Pediatric Blood and Marrow Transplant Consortium (PBMTC) is a voluntary collaboration among pediatric transplant centers in North America and, more currently, Australia. Between 2002 and 2004, the PBMTC made it a requirement that pediatric BMT centers that wished to maintain a membership submit patient information to the PBMTC registry. Although in place, the requirements for reporting resulted in a relatively high-quality database across a broad patient demographic that included patient information from centers that varied significantly in patient volume. The objective of this study was to evaluate the relationship between pediatric BMT center volume and day þ 100 mortality among a large cohort of transplant centers. Herein, we report a concentrated pediatric BMT experience and assess the contribution of individual center volume to the variability in day þ 100 mortality, using three different analyses and controlling for a large number of independent variables.
MATERIALS AND METHODS

Transplant centers
Patient data were derived from 60 independent pediatric transplant centers participating in the PBMTC. Data reported from 2002 to 2004 to the Consortium are derived from all BMTs performed at participating centers, regardless of the patient's enrollment in a clinical trial. Forty-eight of these centers participated in the National Marrow Donor Program, and thirty-two of the centers were approved by the Federation for the Accreditation of Cellular Therapy (FACT) during the study period. Transplant centers and their Principal Investigators are summarized in the Acknowledgements.
Patient population
Included in the analysis were all BMT procedures reported to the PBMTC between 2002 and 2004, inclusive, representing the densest data set of transplants reported to the PBMTC registry. All patient cases were followed through a minimum of day þ 100 post transplant. Data submitted to the PBMTC were obtained directly from the same registration and day þ 100 data fields used by centers to submit to the Center for International Blood and Marrow Transplant Research. All unrelated donor transplant data were subject to audit by the National Marrow Donor Program. Although the PBMTC did not perform an independent audit, missing and inconsistent data fields were clarified through direct query to individual centers by PBMTC Registry personnel. A total of 2991 BMT procedures were conducted at 60 different pediatric BMT centers in North America and reported to the PBMTC during this period. Outcome data for survival at day þ 100 was available for 2718 (91%) patients. Excluded from the analysis were three patients from centers that reported o1 transplant per year during this time period (day þ 100 survival ¼ 100%), seven cases that lacked a patient date of birth and one case that lacked donor information. Also excluded from the analysis were transplants performed on patients older than 18 years of age. A total of 264 eligible patients who were p18 years of age (9%) lacked outcome data. The remaining 2575 patients were included in the analysis. One thousand four hundred and twenty (55.1%) of these procedures were conducted at FACT-accredited centers.
Data elements
Data were collected prospectively and contributed to the PBMTC registry after obtaining informed consent from patient's families and assent from patients, as appropriate, at each transplant center. Patient age was defined on the day of transplant. Pediatric BMT volume was defined as the average number of transplants per year. Engraftment was defined as the first of three consecutive days with an ANC 4500/mm 3 . The primary outcome variable was day þ 100 mortality and includes both transplant-and disease-related mortality. One-year mortality was not considered as an outcome variable as it is influenced by multiple disease-and managementspecific variables that were not included in the PBMTC data set. The investigators were blinded with respect to the association of specific data with the identity of the individual transplant centers.
Forty-six independent data categories were selected a priori to investigate their relationship with day þ 100 mortality. These independent data categories were distributed between nine variables, as follows: three age groups (infant, o1 year; child, from 1 to 6 years; adolescent, from 7 to 18 years); five race-ethnicity groups (Caucasian, Asian, African American, Hispanic and others), two gender groups (male and female), seventeen diagnosis groups (ALL, AML, neuroblastoma, central nervous system tumor, immunodeficiency, myelodysplastic syndrome, aplastic anemia, Hodgkin's disease, non-Hodgkin's lymphoma, BM failure, metabolic disorders, hemoglobin/platelet disorders, chronic myelocytic leukemia, histiocytosis, other solid tumor, malignant disorders not otherwise specified and unknown diagnosis), two conditioning regimen groups (myeloablative and non-myeloablative), two graft manipulation groups (yes and no), eight donor type groups (autologous, syngeneic, HLA-matched sibling, HLA-matched other family member, HLA-mismatched sibling, HLA-matched unrelated donor, HLA-mismatched unrelated donor and allogeneic not otherwise specified), five graft source groups (BM, peripheral blood, cord blood, combination and unknown) and two repeat transplant groups (repeat autologous and repeat allogeneic).
Statistical analysis
Univariable, standard multivariable and hierarchical multivariable analyses were used to assess the volume-outcome relationship while adjusting for 46 independent data categories divided between nine variables that were known-or suspected-mortality risk factors, as detailed above. Continuous variables were analyzed using the Student's t-test, and categorical data were analyzed using w 2 -analysis. We also tested for colinearity between independent variables and found no statistically significant interactions between them. Variables that included a category of 'Unknown' were included in the analysis and were further tested with simulations to confirm that their presence did not influence the significance of other categories within that variable (data not shown). It was decided, a priori, that all independent variables would be included in the final multivariable analyses to retain their influence, regardless of significance in the univariable analyses.
To test the association between the primary outcome variable (day þ 100 mortality) and the primary independent variable of interest (transplant center volume), univariable and multivariable logistic regression analyses were conducted. We considered the association of volume as follows: volume as a continuous variable; volume as a categorical variable in seven equally distributed volume categories; volume as a dichotomous variable, using 20 total transplants per year, 10 total transplants per year, 10 allogeneic transplants per year and 10 'first-time' allogeneic transplants per year as thresholds; and volume divided by quintile. We selected 20 transplants per year as a division point because this volume has been used as a minimum volume threshold for transplant 'Center of Excellence' designation by some third party payors and reimbursement by some state agencies (for example, California Children's Services), and 10 first-time allogeneic transplants per year as a division point consistent with the FACT accreditation requirements for pediatric BMT centers.
A hierarchical logistic regression using a random intercept model was also performed to adjust for patient 'clustering.' In this model, patients represented the primary level and hospitals (transplant centers) represented the secondary level. Further evaluation of individual transplant center contribution to day þ 100 mortality was accomplished by assessment of the intraclass correlation (ICC) using the analysis of variance method. 21 This statistic provides an indication of the contribution of individual transplant centers to the total variation in outcome (day þ 100 mortality).
The association of FACT accreditation with day þ 100 mortality was also investigated. These analyses were based on first-time allogeneic transplant volume. All patient information was managed consistent with the Health Insurance Portability and Accountability Act and the University of California Institution Review Board guidelines. Statistical analyses were conducted using Stata version 11 (StatCorp, LP, College Station, TX, USA) and R.
RESULTS
Transplant and patient characteristics
The 2575 cases evaluated include 893 (35%) autologous transplants, 1671 (65%) allogeneic transplants and 11 (0.4%) syngeneic transplants (Table 1) . These data reflect a slightly higher frequency of unrelated donor (887 or 53%) as compared with related donor (713 or 43%) allogeneic transplants.
ALL, AML and neuroblastoma were the most common diagnoses and, together, accounted for 51% of all transplants performed. The seven most common disease categories accounted for 74% of the transplants performed ( Table 1) . The mean age at transplant was 7.5 years. The median age was 7.5 years, with an interquartile range of 6 years and 13 years.
Day þ 100 mortality Overall day þ 100 mortality rates for selected patient populations and center volume stratifications are shown in Table 2a and Table 2b , respectively. Thirty-six (60%) of the 60 centers included in the analysis performed o20 transplant procedures per year. These centers accounted for 1008 (39%) of the 2575 transplant procedures analyzed. The overall day þ 100 observed mortality was 14.3% with no clear association with center volume (Figure 1 ). Impact of center size on day 100 mortality As shown in Table 3 , statistical significance between transplant center volume and day þ 100 mortality was observed twice, but only in the univariable analysis. This was first observed when volume was grouped into seven volume categories, wherein the largest volume centers had a higher day þ 100 mortality rate (odds ratio (OR) ¼ 1.43, 95% confidence intervals (CI) 1.01-2.04, P ¼ 0.05). The second association was observed when volume was assessed by quartile, wherein the fourth quintile had a lower day þ 100 mortality rate (OR ¼ 0.75, 95% CI 0.56-1.00, P ¼ 0.05). However, when the model adjusted for 46 data categories in both the standard multivariable analysis and in the two-level hierarchical multivariable analysis, there was no association found between transplant center volume and day þ 100 mortality, regardless of volume category (Table 3) .
Subgroup analyses were performed to evaluate whether volume-associated mortality differences were evident when only allogeneic transplants were considered. Results indicate no association between center volume and day þ 100 mortality, whether volume was considered as a continuous variable, categorized into four volume groups, assessed by quintile dichotomized at less than or X20 total transplants per year or dichotomized at less than or X10 allogeneic transplants per year (Table 4) . Similarly, there was no association between transplant center volume and day þ 100 mortality when 971 unrelated donor transplant, mismatched unrelated donor and mismatched related donor transplants were considered, as shown in Table 5 . Equivalent results were obtained if volume was dichotomized at five allogeneic transplants per year or based on total transplant volume (allogeneic and autologous), even though the lowest volume centers in these analyses performed o5 allogeneic BMT per year (data not shown). In addition, an ICC was calculated and found to be 0.0108 (95% CI 0.00-0.02), indicating that differences between transplant center volumes contributed 1.1% of the overall observed differences in day þ 100 mortality after adjusting for other known-and suspected-mortality risk factors.
Impact of FACT accreditation
This analysis included only the results from 1441 'first-time' allogeneic transplants. As shown in Table 6 , transplant center volume was associated with decreased day þ 100 mortality only in the univariable analysis if volume was defined by quintiles, but not after adjusting for other independent variables, as shown in the hierarchical multivariable analysis. Six hundred and thirty (43.7%) of these transplants were completed at centers that were not FACT accredited and had an overall day þ 100 mortality of 17%. There was no association between FACT accreditation and day þ 100 mortality in either the univariable or two-level hierarchical multivariable analysis (OR ¼ 1.12, 95% CI 0.86-1.48 and OR ¼ 1.02, 95% CI 0.75-1.40, respectively).
DISCUSSION
The three primary findings from our analyses are as follows: (1) small volume transplant centers contribute a significant percentage of pediatric transplants within the PBMTC consortium, (2) there is no association between transplant center volume and day þ 100 mortality and (3) among the 60 PBMTC participating centers contributing to this data set, the variability in day þ 100 mortality is 98.9% dependent on factors not specific to individual center size or their accreditation. Although Loberiza et al. 22 suggested that center-specific factors, such as 420 allogeneic transplants per physician per year, correlates with an improved day þ 100 and 1-year mortality in adult allogeneic transplants for leukemia, the current analysis suggests that these factors are either similar between centers within the PBMTC or are not important in the pediatric transplant population.
The European Blood and Marrow Transplant (EBMT) pediatric BMT volume-outcome relationship has also been reported. Klingebiel et al. 18 analyzed 102 haploidentical BMT procedures done at 36 centers over 10 years for pediatric patients with very high-risk AML. Although center volume o23.1 transplants per year did not impact non-relapse mortality, a limited multivariable analysis suggested a correlation with decreased 5-year leukemiafree survival secondary to increased relapse incidence. It remains unclear whether this difference was a direct result of disease variables, the transplant center or differences in post-transplant patient management. Miano et al. 19 analyzed 31 713 pediatric transplants done over 32 years. In a multivariable analysis containing four dichotomous variables, a small, increased risk of day þ 100 mortality was noted for centers with volume o10 versus those performing at least 10 allogeneic transplants per year. Although the limited study population of the former report precluded a more extensive analysis, inclusion of more variables in Table 3 . Pediatric transplant volume-outcome relationship DS Taylor et al the latter multivariable analysis may have better excluded the possibility of a type 1 error. Corroboration of the EBMT center volume findings in these two studies using either a hierarchical analysis at the level of the center or calculation of an ICC, as provided in the present analysis, would help validate their observations. Nevertheless, it is interesting to speculate that volume may be a surrogate marker for differences that exist between EBMT centers that do not exist between PBMTC centers.
The day þ 100 mortality rates reported in the PBMTC database are consistent with mortality from BMTs reported by others. The day þ 100 overall mortality rate (including both disease-and transplant-related mortality) for the 887 unrelated donor transplants was 23 .7% in this data set, and is similar to the Seattle experience of 26.1% day þ 100 overall mortality rate for 88 children treated with unrelated marrow transplantation for ALL between 1987 and 1999, and the 21% transplant-related mortality reported for patients grafted after 1998 by Dini et al. 23, 24 The 18.1% overall mortality (including both disease-and transplantrelated mortality) for all allogeneic BMT in this PBMTC cohort is also consistent with a 13% day þ 100 transplant-related mortality reported by the EBMT during the same time period. 19 The PBMTC overall day þ 100 mortality rate of 22.4% for 450 umbilical cord transplants is also consistent with the 23-39% day þ 100 transplant-related mortality rate among a total of 192 similar transplants performed between 1994 and 2002, as reviewed by Rocha et al. 25 on behalf of the Eurocord and the EBMT Group. Thus, the transplant day þ 100 survival rates within PBMTC participating centers are comparable to other institutions and consortia, and indicates that greater inclusion of smaller transplant centers, as modeled by the PBMTC, does not worsen reported transplant results.
The current analyses demonstrate the utility of structured, aggregate data regarding pediatric BMT procedures and their outcomes, and highlight the implicit challenge in studying this diverse cohort with uncommon diseases that are geographically widespread. The implementation of mechanisms to insure greater inclusion of smaller centers can augment patient accrual to clinical trials, and insure that these procedures are available to meet patient needs and increases direct and long-term care of transplant patients by their primary transplant facility.
An important strength of this study is inclusion of many patient level data variables relevant to patient BMT outcomes. We included 46 categories divided between 9 variables, not just those thought to be significant based on a univariable analysis, to adjust for such factors that are both known and suspected to contribute to risk of day þ 100 mortality. Sub-analyses of higher risk patient populations within this data set also failed to demonstrate a volume-outcome relationship. The lack of a center effect was corroborated by both a hierarchical multivariable analysis and calculation of an ICC. Although the inclusion of a large number of independent variables may decrease the risk of a type 1 error, the 95% CI can be larger than would be present in a more limited evaluation and possibly obfuscate the presence of small, but significant differences. 26 There are several potential limitations of this study. Despite internal validity checks of data that are submitted to the PBMTC, these data were not subjected to an independent audit. Regardless, we believe that the observations noted herein are c Adjusted multivariable analysis: data stratified by transplant center using random intercept model. Odds ratios are relative to lowest volume category, while simultaneously including all other independent variables in the multivariable analysis. The multivariable analysis was performed as described in Materials and methods in the absence of the data category of autologous transplant and repeat autologous transplant. In addition, the diagnosis category of central nervous system tumor was dropped due to colinearity. Categorical, quintiles and dichotomous 10-transplant centers were divided according to number of allogeneic transplants performed per year by increments of 10 transplants per year (categorical), by quintile (quintiles) or between those that performed o10 allogeneic transplants per year and those that performed X10 allogeneic transplants per year (dichotomous 10). e Dichotomous 20-transplant centers were divided between those that performed o20 transplants per year of any type and those that performed X20 transplants per year of any type. Results of only the allogeneic transplants are analyzed.
Pediatric transplant volume-outcome relationship DS Taylor et al not impacted. First, 434% of the transplants reported (unrelated donor transplants) were subject to audit by the National Marrow Donor Program. Second, the data submitted to the PBMTC were derived directly from the same registration and day þ 100 data fields that centers submitted to the Center for International Blood and Marrow Transplant Research; data that were also audited. Third, the primary outcome variable, day þ 100 mortality, is a highly objective measure unlikely compromised by subjective interpretation, and mortality rates within the PBMTC data set are consistent with those reported by others, as outlined above. Fourth, the observed lack of variability in risk-adjusted outcomes attributable to transplant centers, as observed by both a low ICC and no statistical evidence of a volume-outcome relationship in several analyses, supports the integrity of the data despite absence of a formal audit. A second potential limitation is the necessary exclusion of 264 cases, for lack of outcome data and their possible impact on the results reported herein. A detailed comparison of the included and excluded cases revealed a small, statistically significant difference in only the stem cell source and age variables (data not shown). Within these variables, the infant age category had the greatest impact on the results secondary to its importance as an independent risk factor, and skewed distribution between the volume categories with excluded data disproportionately from the 30-40 BMT per year category. Although this may have resulted in a small improvement in the observed day þ 100 outcome of the 30-40 BMT per year volume category, simulations indicated that there were no conditions under which this variable could change the significance of this volume category or alter the conclusions of this study. All other categories for which there was a significant difference between included and excluded populations were less important as an independent risk factor, more evenly distributed between the volume categories, or both.
The outcome variable used in the current study (day þ 100 mortality) is a common endpoint that is generally less influenced by the natural history of the underlying diseases, differences in post-transplant supportive care delivered by non-transplant services and more reflective of acute transplant morbidities. The fact that there was little change in our results despite three different analyses evaluating the impact of transplant center volume is most likely reflective of higher variability between patient-specific factors than between center-specific factors within the PBMTC. Although we did not find an overall average volume-outcome relationship among 60 pediatric BMT centers in the PBMTC database, there could still be individual centers that have higher or lower than expected day þ 100 mortality rates. Our analyses do not suggest that all centers are equal; rather, our analyses conclude that on average, transplant center volume does not significantly contribute to differences in PBMTC center performance as measured by day þ 100 mortality. The current findings suggest that the majority of differences in day þ 100 mortality observed between centers are attributable to identifiable patient-and transplantspecific variables rather than variability between centers. These results may reflect similarity in environment and practice patterns c Adjusted multivariable analysis: data stratified by transplant center using random intercept model. Odds ratios are relative to lowest volume category, while simultaneously including all other independent variables in the multivariable analysis. The multivariable analysis was performed as described in Materials and methods in the absence of the data category of autologous transplant and repeat autologous transplant. In addition, the diagnosis category of central nervous system tumor was dropped due to colinearity. Categorical and dichotomous 10-transplant centers were divided according to number of allogeneic transplants performed per year by increments of 10 transplants per year (categorical) or between those that performed o10 and those that performed X10 allogeneic transplants per year (dichotomous 10). Results of only the URD, mURD and mRD transplants are analyzed.
e Quintiles determined according to number of URD, mURD and mRD transplants performed per year. f Dichotomous 20-transplant centers were divided between those that performed o20 transplants per year of any type and those that performed X20 transplants per year of any type. Results of only the URD, mURD and mRD transplants are analyzed.
between PBMTC transplant centers that result from all programs being within tertiary care pediatric institutions, and that the transplant procedure is not dependent on a mechanical skill set that requires repetition to maintain proficiency. The current findings are most consistent with recent literature evaluating the volume-outcome relationship for acute hospital admissions and medical procedures that are amenable to evidence-based guidelines and clinical pathways. 5, 7, 8, [10] [11] [12] These data support the de-emphasis of center volume as a criterion for accreditation or determination of excellence and support risk-adjusted analysis of individual center performance. Further analyses are required to better determine those specific factors that positively contribute to variability in day þ 100 mortality and a similarly detailed analysis employing a more comprehensive data set to assess impact of center volume on 1-year mortality. Adjusted multivariable analysis: data stratified by transplant center using random intercept model. Odds ratios are relative to lowest volume category, while simultaneously including all other independent variables in the multivariable analysis. The multivariable analysis was performed as described in the Materials and methods in the absence of the data categories of autologous transplant, repeat allogeneic transplant, repeat autologous transplant, malignant disorder not otherwise specified and central nervous system tumor for the lack of data elements. Author contributions: DST is responsible for project concept, experimental design, database structure for analysis, as well as a co-participant in data analysis, critical interpretation of results and principal author of primary manuscript. MD introduced the ICC to the methods, performed the associated statistical analysis and provided critical participation to the writing of the final manuscript. EUS is responsible for extensive data organization, database management and literature research. RR provided data elements for the database and was responsible for internal data quality control. MAP provided critical interpretation of results and review of the manuscript. AG provided critical structure to the PBMTC to permit the organized collection of patient data, initiated the PBMTC data registry, provided critical interpretation of results and review of the final manuscript. KS provided PBMTC leadership that insured data submission to data registry, oversight of center participation in data registry, critical input to study design, result interpretation and review of the manuscript. JPM provided primary statistical expertise and mentoring necessary to perform data analysis, critical assistance in the design of the analysis and interpretation of the results. This author also contributed significantly to writing both the primary and final manuscripts.
